External validation of population pharmacokinetic models of gentamicin in paediatric population from preterm newborns to adolescents

1 E. Germovsek, C. I. S. Barker, M. Sharland and J. F. Standing, Pharmacokinetic-pharmacodynamic modeling in pediatric drug development, and the importance of standardized scaling of clearance, Clin. Pharmacokinet. 58(1) (2019) 39–52; https://doi.org/10.1007/s40262-018-0659-0 Search in Google Scholar

2 H. Kimko and J. Pinheiro, Model-based clinical drug development in the past, present and future: a commentary, Br. J. Clin. Pharmacol. 79(1) (2015) 108–116; https://doi.org/10.1111/bcp.12341 Search in Google Scholar

3 K. J. Downes, A. Hahn, J. Wiles, J. D. Courter and A. A. Vinks, Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics, Int. J. Antimicrob. agents 43(3) (2014) 223–230; https://doi.org/10.1016/j.ijantimicag.2013.11.006 Search in Google Scholar

4 R. F. W. De Cock, C. Piana, E. H. J. Krekels, M. Danhof, K. Allegaert and C. A. J. Knibbe, The role of population PK-PD modelling in paediatric clinical research, Eur. J. Clin. Pharmacol. 67 (2011) 5–16; https://doi.org/10.1007/s00228-009-0782-9 Search in Google Scholar

5 UpToDate: Gentamicin (systemic): Pediatric drug information, 2022; last access date February 20, 2023. Search in Google Scholar

6 M. H. Abdul-Aziz, J.-W. C. Alffenaar, M. Bassetti, H. Bracht, G. Dimopoulos, D. Marriott, M. N. Neely, J.-A. Paiva, F. Pea and F. Sjovall, Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#, Intensive Care Med. 46 (2020) 1127–1153; https://doi.org/10.1007/s00134-020-06050-1 Search in Google Scholar

7 C. J. Hodiamont, A. K. van den Broek, S. L. de Vroom, J. M. Prins, R. A. Mathôt and R. M. van Hest, Clinical pharmacokinetics of gentamicin in various patient populations and consequences for optimal dosing for gram-negative infections: an updated review, Clin. Pharmacokinet. 61 (2022) 1075–1094; https://doi.org/10.1007/s40262-022-01143-0 Search in Google Scholar

8 P. Póvoa, P. Moniz, J. G. Pereira and L. Coelho, Optimizing antimicrobial drug dosing in critically ill patients, Microorganisms 9(7) (2021) Article ID 1401 (27 pages); https://doi.org/10.3390/micro-organisms9071401 Search in Google Scholar

9 J. M. Lanao, M. V. Calvo, J. A. Mesa, A. Martín-Suárez, M. T. Carbajosa, F. Miguelez and A. Domínguez-Gil, Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates, J. Antimicrob. Chemother. 54(1) (2004) 193–198; https://doi.org/10.1093/jac/dkh261 Search in Google Scholar

10 A. M. Jenh, P. D. Tamma and A. M. Milstone, Extended-interval aminoglycoside dosing in pediatrics, The Pediatr. Infect. Dis. J. 30(4) (2011) 338–339; https://doi.org/10.1097/INF.0b013e31820f0f3a Search in Google Scholar

11 S. J. McWilliam, D. J. Antoine, R. L. Smyth and M. Pirmohamed, Aminoglycoside-induced nephrotoxicity in children, Pediatr. Nephrol. 32 (2017) 2015–2025; https://doi.org/10.1007/s00467-016-3533-z Search in Google Scholar

12 F. A. Diepstraten, A. E. Hoetink, M. van Grotel, A. D. R. Huitema, R. J. Stokroos, M. M. van den Heuvel-Eibrik and A. J. M. Meijer, Aminoglycoside-and glycopeptide-induced ototoxicity in children: a systematic review, JAC-Antimicrob. Resist. 3, dlab184 (2021), https://doi.org/10.1093/jacamr/dlab184 Search in Google Scholar

13 A. Smits, P. Annaert and K. Allegaert, Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology, Int. J. Pharm. 452(1–2) (2013) 8–13; https://doi.org/10.1016/j.ijpharm.2012.03.035 Search in Google Scholar

14 H. Lu and S. Rosenbaum, Developmental pharmacokinetics in pediatric populations, J. Pediatr. Pharmacol. Ther. 19(4) (2014) 262–276; https://doi.org/10.5863/1551-6776-19.4.262 Search in Google Scholar

15 Y. A. Bijleveld, M. E. van den Heuvel, C. J. Hodiamont, R. A. Mathôt and T. R. de Haan, Population pharmacokinetics and dosing considerations for gentamicin in newborns with suspected or proven sepsis caused by Gram-negative bacteria, Antimicrob. Agents Chemother. 61(1) (2017) e01304-16; https://doi.org/10.1128/AAC.01304-16 Search in Google Scholar

16 S. J. F. Hartman, R. J. Brüggemann, L. Orriëns, N. Dia, M. F. Schreuder, S. N. De Wildt, Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature, Clin. Pharmacokinet. 59 (2020) 173–205; https://doi.org/10.1007/s40262-019-00813-w Search in Google Scholar

17 N. Thakkar, S. Salerno, C. P. Hornik and D. Gonzalez, Clinical pharmacology studies in critically ill children, Pharm. Res. 34 (2017) 7–24; https://doi.org/10.1007/s11095-016-2033-y Search in Google Scholar

18 D. J. Touw, E. M. Westerman and A. J. Sprij, Therapeutic drug monitoring of aminoglycosides in neonates, Clin. Pharmacokinet. 48 (2019) 71–88; https://doi.org/10.2165/0003088-200948020-00001 Search in Google Scholar

19 M. Crcek, J. Zdovc and M. Kerec Kos, A review of population pharmacokinetic models of gentamicin in paediatric patients, J. Clin. Pharm. Ther. 44 (55) (2019) 659–674; https://doi.org/10.1111/jcpt.12850 Search in Google Scholar

20 L. Martin, N. Jimenez and A. M. Lynn, Developmental pharmacokinetics and pharmacodynamics of parenteral opioids and nonsteroidal anti-inflammatory drugs in neonates and infants, Colomb. J. Anestesiol. 45 (2017), 72–79; https://doi.org/10.1016/j.rcae.2016.11.011 Search in Google Scholar

21 A. N. Mian and G. J. Schwartz, Measurement and estimation of glomerular filtration rate in children, Adv. Chronic Kidney Dis 24 (2017) 348–356; https://doi.org/10.1053/j.ackd.2017.09.011 Search in Google Scholar

22 L. Kahl and H. K. Hughes, The Harriet Lane Handbook, 21^nd ed., Elsevier, Amsterdam 2018. Search in Google Scholar

23 ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population - Scientific guideline 2017; https://www.ema.europa.eu/en/ich-e11r1-step-5-guideline-clinical-investigation-medicinal-products-pediatric-population-scientific; last access date February 20, 2023. Search in Google Scholar

24 M.-A. Decrocq-Rudler, A. H. X. P. C. Kwong, L. Meunier, J. Fraisse, J. Ursic-Bedoya and S. Khier, Can we predict individual concentrations of tacrolimus after liver transplantation? Application and tweaking of a published population pharmacokinetic model in clinical practice, Ther. Drug Monit. 43(4) (2921) 490–498; https://doi.org/10.1097/FTD.0000000000000867 Search in Google Scholar

25 A. Chan Kwong, A. O’Jeanson and S. Khier, Model-informed therapeutic drug monitoring of meropenem in critically ill patients: improvement of the predictive ability of literature models with the PRIOR approach, Eur. J. Drug Metab. Pharmacokinet. 46 (2021) 415–426; https://doi.org/10.1007/s13318-021-00681-5 Search in Google Scholar

26 A. Gomes, L. van der Wijk, J. H. Proost, B. Sinha and D. J. Touw, Pharmacokinetic modeling of gentamicin in treatment of infective endocarditis: Model development and validation of existing models, PloS One 12(5) (2017) e0177324 (13 pages); https://doi.org/10.1371/journal.pone.0177324 Search in Google Scholar

27 J. H. Hughes, D. M. H. Tong, S. S. Lucas, J. D. Faldasz, S. Goswami and R. J. Keizer, Continuous learning in model-informed precision dosing: a case study in pediatric dosing of vancomycin, Clin. Pharmacol. Ther. 109(1) (2021) 233–242; https://doi.org/10.1002/cpt.2088 Search in Google Scholar

28 W. Zhao, F. Kaguelidou, V. Biran, D. Zhang, K. Allegaert, E. V. Capparelli, N. Holford, T. Kimura, Y. L. Lo, J. E. Peris, External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings, Br. J. Clin. Pharmacol. 75(4) (2013) 1068–1080; https://doi.org/10.1111/j.1365-2125.2012.04406.x Search in Google Scholar

29 C. Schräpel, L. Kovar, D. Selzer, U. Hofmann, F. Tran, W. Reinisch, M. Schwab and T. Lehr, External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease, Pharmaceutics 13(9) (2021) Article ID 1368 (21 pages); https://doi.org/10.3390/pharmaceutics13091368 Search in Google Scholar

30 K. R. Knøsgaard, D. J. R. Foster, M. Kreilgaard, E. Sverrisdóttir, R. N. Upton and J. N. van den Anker, Pharmacokinetic models of morphine and its metabolites in neonates: Systematic comparisons of models from the literature, and development of a new meta-model, Eur. J. Pharm. Sci. 92 (2016) 117–130; https://doi.org/10.1016/j.ejps.2016.06.026 Search in Google Scholar

31 D. M. Tong, J. H. Hughes and R. J. Keizer, Evaluating and improving neonatal gentamicin pharmacokinetic models using aggregated routine clinical care data, Pharmaceutics 14(10) (2022) Article ID 2089 (14 pages); https://doi.org/10.3390/pharmaceutics14102089 Search in Google Scholar

32 A. H.-X. Chan Kwong, E. A. Calvier, D. Fabre, F. Gattacceca and S. Khier, Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine, J. Pharmacokinet. Pharmacodyn. 47 (2020) 431–446; https://doi.org/10.1007/s10928-020-09695-z Search in Google Scholar

33 A. Duong, C. Simard, D. Williamson and A. Marsot, Model re-estimation: An alternative for poor predictive performance during external evaluations? Example of gentamicin in critically ill patients, Pharmaceutics 14(7) (2022) 1426; https://doi.org/10.3390/pharmaceutics14071426 Search in Google Scholar

34 C. C. Llanos-Paez, C. E. Staatz, R. Lawson and S. Hennig, A population pharmacokinetic model of gentamicin in pediatric oncology patients to facilitate personalized dosing, Antimicrob. Agents Chemother. 61(8) (2017) e00205-17; https://doi.org/10.1128/AAC.00205-17 Search in Google Scholar

35 S. A. Lopez, H. Mulla, A. Durward and S. M. Tibby, Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness, Pediatr. Crit. Care Med. 11(2) (2010) 267–274; https://doi.org/10.1097/PCC.0b013e3181b80693 Search in Google Scholar

36 R. F. W. De Cock, K. Allegaert, J. M. Brussee, C. M. T. Sherwin, H. Mulla, M. de Hoog, J. N. van den Anker, M. Danhof and C. A. J. Knibbe, Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration, Pharm. Res. 31 (2014) 2643–2654;, https://doi.org/10.1007/s11095-014-1361-z Search in Google Scholar

37 A. Alsultan, M. Abouelkheir, Y. Elsharawy, A. Alkoraishi, R. Osman, M. N. Neely, W. Mansy and S. Algahtani, Optimizing gentamicin dosing in pediatrics using monte carlo simulations, Pediatr. Infect. Dis. J. 38(4) (2019) 390–395; https://doi.org/10.1097/INF.0000000000002120 Search in Google Scholar

38 C. C. Llanos-Paez, C. E. Staatz, R. Lawson and S. Hennig, Differences in the pharmacokinetics of gentamicin between oncology and nononcology pediatric patients, Antimicrob. Agents Chemother. 64(2) (2020) e01730-19; https://doi.org/10.1128/AAC.01730-19 Search in Google Scholar

39 H. Wang, C. Sherwin, J. V. S. Gobburu and V. Ivaturi, Population pharmacokinetic modeling of gentamicin in pediatrics, J. Clin. Pharmacol. 59(12) (2019) 1584–1596; https://doi.org/10.1002/jcph.1479 Search in Google Scholar

40 R. H. Ghoneim, A. K. Thabit, M. O. Lashkar and A. S. Ali, Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation, Ital. J. Pediatr. 47 (2021) Article ID 167 (8 pages); https://doi.org/10.1186/s13052-021-01114-4 Search in Google Scholar

41 H. S. Al-Sallami, A. Goulding, A. Grant, R. Taylor, N. Holford and S. B. Duffull, Prediction of fat-free mass in children, Clin. Pharmacokinet. 54 (2015) 1169–1178; https://doi.org/10.1007/s40262-015-0277-z Search in Google Scholar

42 J. Valles, J. Rello, A. Ochagavía, J. Garnacho and M. A. Alcalá, Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival, Chest 123(5) (2003) 1615–1624; https://doi.org/10.1378/chest.123.5.1615 Search in Google Scholar

43 A. Coste, G. Deslandes, L. Jalin, S. Corvec, J. Caillon, D. Boutoille, M. Grégoire and C. Bretonnière, PK/PD targets of amikacin and gentamicin in ICU patients, Méd. Mal. Infect. 50(8) (2020) 709–714; https://doi.org/10.1016/j.medmal.2019.12.003 Search in Google Scholar

44 A. A. Marsot, A. Boulamery, B. Bruguerolle and N. Simon, Population pharmacokinetic analysis during the first 2 years of life: an overview, Clin. Pharmacokinet. 51 (2012) 787–798; https://doi.org/10.1007/s40262-012-0015-8 Search in Google Scholar

45 F. Ceriotti, J. C. Boyd, G. Klein, J. Henny, J. Queralto, V. Kairisto and M. Panteghini, Reference intervals for serum creatinine concentrations: assessment of available data for global application, Clin. Chem. 54(3) (2008) 559–566; https://doi.org/10.1373/clinchem.2007.099648 Search in Google Scholar